4-(3,4-dimethoxyphenyl)but-3-yn-1-ol | 160360-45-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3,4-dimethoxyphenyl)but-3-yn-1-ol
• 英文别名: 4-(3,4-dimethoxyphenyl)-3-butyn-1-ol
• CAS: 160360-45-2
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: BTSAKSUXEFQZCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3,4-dimethoxyphenyl)but-3-yn-1-ol 在 palladium on activated charcoal 氢气 作用下， 反应 4.0h， 生成 4-(3,4-dimethoxyphenyl)butanal
  参考文献：
  名称：

  The enantiospecific Nicholas reaction

  摘要：

  The enantiospecific Nicholas reaction, i.e. cobalt-promoted Friedel-Crafts reaction leading from chiral reactant to chiral product, was demonstrated for the first time.

  DOI：

  10.1016/s0040-4039(00)78489-9
• 作为产物：
  描述：

  4-溴黎芦醚 、 3-丁炔-1-醇 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 二异丙胺 作用下， 反应 0.75h， 以89%的产率得到4-(3,4-dimethoxyphenyl)but-3-yn-1-ol
  参考文献：
  名称：

  The enantiospecific Nicholas reaction

  摘要：

  The enantiospecific Nicholas reaction, i.e. cobalt-promoted Friedel-Crafts reaction leading from chiral reactant to chiral product, was demonstrated for the first time.

  DOI：

  10.1016/s0040-4039(00)78489-9

文献信息

• Catechol carboxylic acids
  申请人：Hoffmann-La Roche Inc.

  公开号：US05025036A1

  公开（公告）日：1991-06-18

  The invention relates to catechol carboxylic acid derivatives of the formula ##STR1## wherein, R.sub.1 is ##STR2## acetyl, hydrogen, hydroxy or alkanoyloxy, R.sub.2 is ##STR3## hydroxy, hydrogen or alkanoyloxy, wherein R is hydrogen, lower alkyl or --(CH.sub.2).sub.n --N--(lower alkyl).sub.2, R.sub.3 is hydrogen, lower alkyl or amino, R.sub.4 is hydrogen, lower alkyl, halogen or amino A is ##STR4## wherein, R.sub.5 is hydrogen or acyl, R.sub.6 is hydrogen, halogen, lower alkyl, aryl or cycloalkyl, and R.sub.7 and R.sub.8, independently, are hydrogen, lower alkyl or halogen, or A is ##STR5## wherein, R.sub.5 is hydrogen or acyl, R.sub.9 is hydrogen, lower alkyl, R.sub.10 is hydrogen, lower alkyl or halogen, R.sub.11 is hydrogen, lower alkyl, cycloalkyl or halogen, m is 0 or 1, n is an integer of 2-10, provided, that no more than one of R.sub.1 or R.sub.2 can be hydroxy, alkanoyloxy or ##STR6## and when R is hydrogen, salts thereof with pharmaceutically acceptable bases or when R is --(CH.sub.2).sub.n --N--(lower alkyl).sub.2, salts thereof with pharmaceutically acceptable acids. The compounds of formula I are useful as agents for the treatment of inflammatory diseases such as arthritis, inflammatory bowel disease such as colitis, cardiovascular diseases such as myocardial ischemia, skin diseases such as psoriasis by topical administration, and bronchopulmonary diseases such as asthma.

  这项发明涉及公式##STR1##的儿茶酚羧酸衍生物，其中，R.sub.1为##STR2##乙酰基，氢，羟基或烷酰氧基，R.sub.2为##STR3##羟基，氢或烷酰氧基，其中R为氢，低烷基或--(CH.sub.2).sub.n --N--(低烷基).sub.2，R.sub.3为氢，低烷基或氨基，R.sub.4为氢，低烷基，卤素或氨基，A为##STR4##其中，R.sub.5为氢或酰基，R.sub.6为氢，卤素，低烷基，芳基或环烷基，而R.sub.7和R.sub.8，独立地，为氢，低烷基或卤素，或A为##STR5##其中，R.sub.5为氢或酰基，R.sub.9为氢，低烷基，R.sub.10为氢，低烷基或卤素，R.sub.11为氢，低烷基，环烷基或卤素，m为0或1，n为2-10的整数，前提是R.sub.1或R.sub.2中不超过一个可以是羟基，烷酰氧基或##STR6##，当R为氢时，其与药学上可接受的碱盐，或当R为--(CH.sub.2).sub.n --N--(低烷基).sub.2时，其与药学上可接受的酸盐。公式I的化合物可用作治疗类风湿性关节炎、炎症性肠病如结肠炎、心血管疾病如心肌缺血、皮肤疾病如牛皮癣经局部给药治疗，以及支气管肺部疾病如哮喘的药物。
• GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE
  申请人：SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED

  公开号：US20210115082A1

  公开（公告）日：2021-04-22

  The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

  本发明公开了一种由III式表示的糖苷化合物，以及其制备方法、组合物、用途和中间体。本发明提供的糖苷化合物具有简单的制备方法，可以显著增加VEGF-A mRNA的表达，并且在促进血管生成方面具有有效性。这为开发具有促血管生成活性的药物治疗脑梗死、脑卒中、心肌梗死和下肢缺血微循环障碍提供了可靠的保证。
• Cascade Reaction of Alkynols and 7-Oxabenzonorbornadienes Involving Transient Hemiketal Group Directed C–H Activation and Synergistic Rh^III/Sc^III Catalysis
  作者：Deng Yuan Li、Liang Liang Jiang、Shuang Chen、Zheng Lu Huang、Li Dang、Xin Yan Wu、Pei Nian Liu

  DOI：10.1021/acs.orglett.6b02587

  日期：2016.10.7

  As the first cascade C–H activation directed by a transient group, reaction of alkynols and 7-oxabenzonorbornadienes has been achieved via synergistic rhodium and scandium catalysis to afford spirocyclic dihydrobenzo[a]fluorenefurans. This transformation proceeds by a transient hemiketal group directed C–H activation, dehydrative naphthylation, and intramolecular Prins-type cyclization. Mechanistic

  作为由一个瞬态基团控制的第一个级联C–H活化，炔醇与7-氧杂苯并降冰片二烯的反应已通过协同的铑和scan催化作用而得到，以提供螺环二氢苯并[ a ]芴呋喃。这种转化是通过一个半胱氨酸基团直接引导C–H活化，脱水萘化和分子内Prins型环化而进行的。机理研究和密度泛函理论计算表明，决定速率的步骤是C–H键断裂，瞬态半酮基和协同Rh III / Sc III催化均起关键作用。
• Substituted naphthalene carboxylic acids
  申请人：Hoffmann-La Roche Inc.

  公开号：US04937373A1

  公开（公告）日：1990-06-26

  The invention relates to substituted naphthalene carboxylic acid derivatives of the formula ##STR1## wherein one of R.sub.1 and R.sub.2 is ##STR2## and the other is hydrogen, wherein R is hydrogen or lower alkyl, R.sub.10 is hydrogen or lower alkyl, and m is 0 or 1 A is ##STR3## wherein R.sub.3 is hydrogen or acyl, R.sub.4 is a hydrogen, halogen, lower alkyl, aryl or cycloalkyl, R.sub.5 and R.sub.6 independently are hydrogen or halogen, and n is an integer from 2-10, or A is ##STR4## wherein R.sub.3 is hydrogen or acyl, R.sub.7 is hydrogen or lower alkyl, R.sub.8 and R.sub.9, independently, are hydrogen, lower alkyl or halogen, t is 0 or 1, and n is an integer from 2-10, and, when R.sub.10 is lower alkyl, enantiomers and racemates thereof, and, when R is hydrogen, salts thereof with pharmaceutically acceptable bases.

  该发明涉及以下结构的取代萘羧酸衍生物的化学式：其中R.sub.1和R.sub.2中的一个是，另一个是氢，其中R是氢或较低的烷基，R.sub.10是氢或较低的烷基，m为0或1，A为其中R.sub.3是氢或酰基，R.sub.4是氢、卤素、较低的烷基、芳基或环烷基，R.sub.5和R.sub.6分别为氢或卤素，n为2-10的整数，或A为其中R.sub.3是氢或酰基，R.sub.7是氢或较低的烷基，R.sub.8和R.sub.9独立地为氢、较低的烷基或卤素，t为0或1，n为2-10的整数，当R.sub.10为较低的烷基时，其对映体和消旋体，当R为氢时，其与药用可接受的碱形成的盐。
• Glycoside compound and preparation method therefor, composition, application, and intermediate
  申请人：SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED

  公开号：US11325937B2

  公开（公告）日：2022-05-10

  The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

  本发明公开了一种由式 III 表示的糖苷化合物及其制备方法、组合物、用途和中间体。本发明提供的苷类化合物制备方法简单，能显著提高血管内皮生长因子-A mRNA的表达，有效促进血管生成。这为开发治疗脑梗塞脑中风、心肌梗塞、下肢缺血性微循环障碍等具有促血管生成活性的药物提供了可靠保证。